{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:48:29Z","timestamp":1790938109058,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2021R1F1A1064498"],"award-info":[{"award-number":["2021R1F1A1064498"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Severance Hospital Research Fund for Clinical Excellence","award":["C- 2022-0037"],"award-info":[{"award-number":["C- 2022-0037"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A consolidation strategy has not been established for transplant-ineligible elderly patients with primary central nervous system lymphoma (PCNSL). In this study, we aimed to retrospectively evaluate the clinical outcomes of etoposide and cytarabine (EA) as consolidation chemotherapy for transplant-ineligible patients with PCNSL following high-dose methotrexate (MTX)-based induction chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Between 2015 and 2021, newly diagnosed transplant-ineligible patients with PCNSL with diffuse large B-cell lymphoma were consecutively enrolled. All enrolled patients were over 60 years old and received EA consolidation after achieving a complete or partial response following induction chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 85 patients who achieved a complete or partial response to MTX-based induction chemotherapy, 51 received EA consolidation chemotherapy. Among the 25 (49.0%, 25\/51) patients in partial remission before EA consolidation, 56% (n\u2005=\u200514) achieved complete remission after EA consolidation. The median overall survival and progression-free survival were 43 and 13 months, respectively. Hematological toxicities were most common, and all patients experienced grade 4 neutropenia and thrombocytopenia. Forty-eight patients experienced febrile neutropenia during consolidation chemotherapy, and 4 patients died owing to treatment-related complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>EA consolidation chemotherapy for transplant-ineligible, elderly patients with PCNSL improved response rates but showed a high relapse rate and short progression-free survival. The incidences of treatment-related mortality caused by hematologic toxicities and severe infections were very high, even after dose modification. Therefore, the use of EA consolidation should be reconsidered in elderly patients with PCNSL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae059","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T21:44:40Z","timestamp":1712439880000},"page":"e796-e802","source":"Crossref","is-referenced-by-count":6,"title":["Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5505-0142","authenticated-orcid":false,"given":"Yu Ri","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine , Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2651-6403","authenticated-orcid":false,"given":"Hyunsoo","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine , Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8859-3573","authenticated-orcid":false,"given":"Soo-Jeong","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hemato-Oncology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine , Yongin , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7926-9285","authenticated-orcid":false,"given":"Haerim","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine , Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3544-0060","authenticated-orcid":false,"given":"Hye Won","family":"Kook","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine , Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8832-1412","authenticated-orcid":false,"given":"Ji Eun","family":"Jang","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine , Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-0921","authenticated-orcid":false,"given":"June-Won","family":"Cheong","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine , Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-8436","authenticated-orcid":false,"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine , Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"key":"2024060305561127900_CIT0001","first-page":"1414","article-title":"Age, gender, and racial differences in incidence and survival in primary CNS lymphoma","volume-title":"Br J Cancer.","author":"Villano","year":"2011"},{"key":"2024060305561127900_CIT0002","first-page":"687","article-title":"The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades","volume-title":"Neuro Oncol","author":"Mendez","year":"2018"},{"key":"2024060305561127900_CIT0003","first-page":"1822","article-title":"Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015","volume-title":"Leukemia.","author":"van der Meulen","year":"2017"},{"issue":"3","key":"2024060305561127900_CIT0004","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.14069","article-title":"The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma","volume":"174","author":"Cho","year":"2016","journal-title":"Br J Haematol."},{"key":"2024060305561127900_CIT0005","first-page":"1642","article-title":"The role of autologous stem cell transplantation in primary central nervous system lymphoma","volume-title":"Blood.","author":"Ferreri","year":"2016"},{"key":"2024060305561127900_CIT0006","first-page":"37","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume-title":"Neuro Oncol","author":"Hoang-Xuan","year":"2023"},{"key":"2024060305561127900_CIT0007","first-page":"417","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S","volume-title":"Br J Haematol.","author":"Shiels","year":"2016"},{"key":"2024060305561127900_CIT0008","first-page":"454","article-title":"Evolving treatments for primary central nervous system lymphoma","volume-title":"Am Soc Clin Oncol Educ Book","author":"Ferreri","year":"2019"},{"key":"2024060305561127900_CIT0009","first-page":"859","article-title":"Long-term survival in primary CNS lymphoma","volume-title":"J Clin Oncol.","author":"Abrey","year":"1998"},{"key":"2024060305561127900_CIT0010","first-page":"e510","article-title":"Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial","volume-title":"Lancet Haematol","author":"Ferreri","year":"2017"},{"issue":"10","key":"2024060305561127900_CIT0011","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/archneur.62.10.1595","article-title":"Delayed neurotoxicity in primary central nervous system lymphoma","volume":"62","author":"Omuro","year":"2005","journal-title":"Arch Neurol."},{"issue":"3","key":"2024060305561127900_CIT0012","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-008-9716-0","article-title":"Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy","volume":"91","author":"Correa","year":"2009","journal-title":"J Neurooncol."},{"issue":"30","key":"2024060305561127900_CIT0013","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","article-title":"Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol."},{"key":"2024060305561127900_CIT0014","first-page":"1036","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume-title":"Lancet Oncol.","author":"Thiel","year":"2010"},{"key":"2024060305561127900_CIT0015","first-page":"3061","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume-title":"J Clin Oncol.","author":"Rubenstein","year":"2013"},{"key":"2024060305561127900_CIT0016","first-page":"2318","article-title":"How I treat CNS lymphomas","volume-title":"Blood.","author":"Rubenstein","year":"2013"},{"key":"2024060305561127900_CIT0017","first-page":"e296","article-title":"Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients","volume-title":"Haematologica.","author":"Birsen","year":"2018"},{"key":"2024060305561127900_CIT0018","first-page":"1146","article-title":"Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI","volume-title":"Clin Cancer Res.","author":"Wieduwilt","year":"2012"},{"key":"2024060305561127900_CIT0019","first-page":"1537","volume-title":"Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in","author":"Nabors","year":"2020"},{"key":"2024060305561127900_CIT0020","first-page":"5711","article-title":"Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model","volume-title":"J Clin Oncol.","author":"Abrey","year":"2006"},{"key":"2024060305561127900_CIT0021","first-page":"266","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume-title":"J Clin Oncol.","author":"Ferreri","year":"2003"},{"issue":"22","key":"2024060305561127900_CIT0022","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol."},{"key":"2024060305561127900_CIT0023","first-page":"e251","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume-title":"Lancet Haematol","author":"Omuro","year":"2015"},{"key":"2024060305561127900_CIT0024","first-page":"1512","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume-title":"Lancet","author":"Ferreri","year":"2009"},{"key":"2024060305561127900_CIT0025","first-page":"4643","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10","volume-title":"J Clin Oncol.","author":"DeAngelis","year":"2002"},{"issue":"31","key":"2024060305561127900_CIT0026","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol."},{"key":"2024060305561127900_CIT0027","first-page":"3896","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume-title":"Blood.","author":"Boehme","year":"2009"},{"issue":"3","key":"2024060305561127900_CIT0028","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.2001.19.3.742","article-title":"Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma","volume":"19","author":"Soussain","year":"2001","journal-title":"J Clin Oncol."},{"key":"2024060305561127900_CIT0029","first-page":"846","article-title":"High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)","volume-title":"Leukemia.","author":"Fritsch","year":"2017"},{"key":"2024060305561127900_CIT0030","first-page":"621","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u2018proof of concept\u2019 phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)","volume-title":"Ann Oncol.","author":"Ghesquieres","year":"2019"},{"key":"2024060305561127900_CIT0031","first-page":"1620","article-title":"Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary cns lymphoma: NRG Oncology RTOG 0227","volume-title":"J Clin Oncol.","author":"Glass","year":"2016"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyae059\/58038417\/oyae059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyae059\/58038417\/oyae059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T14:41:09Z","timestamp":1717425669000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/6\/e796\/7641867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,6]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae059","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2024,4,6]]}}}